Dubbed as the most severe and deadly outbreak, the Ebola menace in West Africa has caught the attention of GlaxoSmithKline plc (ADR) (NYSE:GSK) and National institute of health. CNBC’s Meg Tirrell reports that NIH and GlaxoSmithKline have partnered to develop a vaccine that is said to have had immense success in primates, but yet to be tested in Humans.
The studies are to be used to ascertain whether the vaccine is safe and also its ability to prompt an immune response, able to combat the Ebola virus. No humans are to be infected’ with the Ebola virus during the course of the study.
{iframe}http://basicsmedia.com/glaxosmithkline-plc-adr-nysegsk-and-nih-spearheading-development-of-ebola-vaccine-10790{/iframe}